Navigation Links
FDA Grants Soligenix Fast Track Designation for OrbeShield(TM) for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
Date:1/29/2013

p>

About GI ARS

ARS occurs after toxic radiation exposure and involves several organ systems, notably the bone marrow the GI tract and later the lungs. In the event of a nuclear disaster or terrorist detonation of a nuclear bomb, casualties exposed to >2 Gy are at high risk for development of clinically significant ARS. Exposure to high doses of radiation exceeding 10-12 Gy causes acute GI injury which can result in death in 5-15 days.  The GI tract is highly sensitive due to the requirement for incessant proliferation of crypt stem cells and production of mucosal epithelium. The extent of injury to the bone marrow and the GI tract are the principal determinants of survival after exposure to TBI.  Although the hematopoietic syndrome has the potential to be rescued by bone marrow transplantation or growth factor administration, there is no established treatment or preventive measure for the GI damage that results from high-dose radiation exposure. Therefore, there is an urgent need to develop specific medical countermeasures against the lethal pathophysiological manifestations of radiation-induced GI injury.

About OrbeShieldTM

OrbeShieldTM contains BDP, a highly potent, topically active corticosteroid that has a local effect on inflamed tissue. OrbeShieldTM is formulated for oral administration in GI ARS patients as a single product consisting of two tablets; one tablet is intended to release BDP in the proximal portions of the GI tract and the other tablet is intended to release BDP in the distal portions of the GI tract.  BDP has been marketed in the United States and worldwide since the early 1970s as the active pharmaceutical ingredient in inhalation products for the treatment of patients with allergic rhinitis and asthma. Oral BDP may also have application in treating other GI disorders characterized by severe inflammation such as Crohn's disease and ra
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Jersey Health Foundation Awards First Two Innovation Stage Funding Grants
2. Artemis Diagnostics awarded two grants from Technology Strategy Board to develop cancer imaging technology
3. New Jersey Health Foundation Commits $2 Million to Fund Grants
4. FDA Grants Orphan Drug Status To Morphoteks Amatuximab (MORAb-009)
5. FDA Grants Soligenix Fast Track Designation for SGX203 for the Treatment of Pediatric Crohns Disease
6. ViiV Healthcare commits nearly £4M in Positive Action for Children Fund grants for programmes focused on alleviating burden of HIV on women and children
7. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
8. As Global Telemedicine Market Reaches $2.5 Billion, Industry Leaders Gather in San Diego to Discuss Grants, Funding, Vendor Selection, Credentialing, and More
9. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
10. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
11. U.S. FDA Grants Priority Review to Bedaquiline (TMC207) for Multi-Drug Resistant Tuberculosis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... 29 Asahi Kasei Medical Co., Ltd. is pleased to ... MF-SL, its new range of microfilters for bioprocessing applications. Designed specifically ... biopharmaceutical manufacturers to improve the efficiency and effectiveness of their protein ... , ...
... IRIDEX Corporation (Nasdaq: IRIX ) today announced that it will release its ... August 5, 2010 .  In conjunction with the release, the Company will ... Eastern Time on Thursday, August 5, 2010 ... , , ...
Cached Medicine Technology:Launch of BioOptimal™ MF-SL Microfilters for Bioprocessing 2IRIDEX Announces Second Quarter 2010 Conference Call and Release Date 2
(Date:4/18/2014)... University School of Medicine researchers have been awarded two-year ... Novo Nordisk announced this month. Of the 110 initial ... Biologics Science Forum Program, only four projects were funded, ... They are Jonathan Powell, M.D., Ph.D.; G. William Wong, ... Powell, a professor of oncology, will use his $500,000 ...
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at Virginia ... blocking a particular molecule in metastatic breast cancer reduces ... of lung metastases. BRI scientists have found in models ... tumors by 60 - 80 percent and can keep ... The $1.8 million five-year grant comes from the National ...
(Date:4/18/2014)... 18, 2014) ― A new study in the ... in health-related Google searches reveals a recurring pattern that ... , Investigators from San Diego State University, the ... Campaigns, analyzed "healthy" Google searches (searches that included the ... originating in the U.S. from 2005 to 2012. They ...
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... in non-cancerous prostate tissue may have nearly twice the ... no inflammation, according to results of a new study ... Center. , The link between persistent inflammation and cancer ... cancer those with a Gleason score between 7 ... aggressive and rapidly growing prostate cancers. , "What we,ve ...
Breaking Medicine News(10 mins):Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New research shows people are thinking about their health early in the week 2Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3
... bog outshines 19 commonly eaten fruits for the ... latest,Agricultural Research Service Report from USDA, containing the ... foods, shows cranberries,score among the highest of all ... The report includes antioxidant values for a ...
... Children with autism have normal-size heads at birth but ... of age, a period that precedes the onset of ... disorder, according to new research from the University of ... aberrant growth is present in children who have the ...
... Conn.A protein has been found that influences the response of ... such as occurs during a heart attack, a team of ... This finding may present a new therapeutic approach to treating ... The protein, macrophage migration inhibitory factor (MIF), was found to ...
... Bay Park to be the focus of this inaugural ... ... An unclimbed mountain near Mount Abbe,in the northern reaches of Alaska,s ... Expedition for Cancer Research, a quest,sponsored by Fred Hutchinson Cancer Research ...
... 30 Prime Therapeutics (Prime) has,joined the Center ... from,the pharmacy benefit manager (PBM) industry. The Center ... collaborates with leading,organizations to develop and promote innovative ... the health of employees. Members,of the Center represent ...
... estrogen 55 times faster , , WEDNESDAY, Jan. 30 (HealthDay ... release a potentially harmful chemical 55 times faster than ... found in the plastics that make up water bottles, ... acts as an environmental estrogen and can disrupt the ...
Cached Medicine News:Health News:Cranberries' Antioxidant Level Tops List in USDA Report 2Health News:Cranberries' Antioxidant Level Tops List in USDA Report 3Health News:Accelerated head growth can predict autism before behavioral symptoms start 2Health News:Hutchinson Center Announces First Unclimbed Mountain to be Tackled by Big Expedition for Cancer Research 2Health News:Prime Therapeutics Becomes First PBM to Join the Center for Health Value Innovation 2Health News:Heating Plastic Bottles Releases Potentially Harmful Chemical 2Health News:Heating Plastic Bottles Releases Potentially Harmful Chemical 3
... is an automated, multiparametric immunoassay ... device stores the calibration in ... the cost-per-patient result. Plus, with ... ease of use and uni/bi-directional ...
Alpha prime immunoassay system features unsurpassed quality of results, full automation of EIA tests for microplate applications, complete walk-away, up to 18 different assays per run, photometric an...
... Vitros 250 is a flexible ... in multiple environments small ... clinics and satellite locations. The ... dilution, and can be automated ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Medicine Products: